Gold ticks up but remains pressured by Fed rate caution, easing trade fears
Investing.com - Leerink Partners has raised its price target on Ionis Pharmaceuticals (NASDAQ:IONS) to $72.00 from $68.00 while maintaining an Outperform rating on the stock. The new target closely aligns with the current trading price of $71.88, with the stock trading near its 52-week high of $74.42.
The adjustment follows Ionis Pharmaceuticals’ third-quarter 2025 earnings report, according to Leerink Partners. The $11.46 billion market cap company has shown revenue growth of 16.05% over the last twelve months.
The research firm updated its financial model for Ionis based on the quarterly disclosures, increasing estimates for Tryngolza and Wainua in FCS and ATTR-PN indications.
These upward revisions were partially offset by moderating estimates for Dawnzera, Leerink noted in its analysis.
Despite the adjustments to individual product forecasts, Leerink Partners maintained its overall positive outlook on the stock with the Outperform rating.
In other recent news, Ionis Pharmaceuticals reported its third-quarter 2025 earnings, significantly surpassing analysts’ expectations. The company announced an earnings per share (EPS) of -$0.80, which was a notable improvement over the forecasted -$1.22. Revenue also exceeded predictions, reaching $157 million compared to the anticipated $130.76 million. These results highlight the company’s stronger-than-expected financial performance in the recent quarter. Despite these positive earnings and revenue figures, the stock experienced a slight pre-market decline. However, the focus remains on the company’s ability to outperform market expectations. Investors will likely keep an eye on how Ionis Pharmaceuticals continues to manage its financials in the coming quarters. These developments are part of the ongoing updates regarding the company’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.